top of page

Weight Loss with GLP-1: Guaranteed Results, But What's the Diet Impact?

Topic of the Month on ModernWeight: Diet and Exercise on GLP-1s!

Head to the Social Hub to discuss diet and exercise routines when taking GLP-1 medications.


AOMs in the News


This Week's Featured Post

Weight Loss Guaranteed! But What Impact on Your Diet?


GLP-1 and GIP/GLP-1 receptor agonists have revolutionized weight loss treatment, but what do they mean for your diet? Understanding the dietary impacts of these medications is crucial for maintaining overall health while achieving weight loss goals. This week's featured post delves into the dietary changes and nutritional considerations essential for patients on GLP-1 drugs.

A recent review by Hugo Francisco de Souza, published in the journal Obesity Pillars, highlights the dietary impacts of GLP-1 and GIP/GLP-1 receptor agonists on obesity and type 2 diabetes (T2D) patients. The review found a significant reduction in total caloric intake among patients, ranging from 16-39%. However, there is a notable gap in research regarding protein and micronutrient intake. The authors recommend future studies to assess these dietary components and include registered dietitian nutritionists (RDNs) in the research teams.


Why it matters: While GLP-1 and GIP/GLP-1 receptor agonists are effective for weight loss, they can lead to reduced intake of essential nutrients. This calls for better nutritional guidance for patients to ensure balanced diets that support overall health. Future studies should focus on evaluating protein and micronutrient intake to provide comprehensive dietary recommendations for patients on these medications.


Roche Oral GLP-1 Agonist Scores in Early Trial

Roche has announced promising interim results from a Phase I trial for its oral small molecule GLP-1 receptor agonist, CT996. The drug, aimed at treating both type 2 diabetes and obesity, demonstrated clinically meaningful weight loss, with participants without type 2 diabetes experiencing a mean weight loss of 6.1% within four weeks. The drug market is seeing intense competition with the emergence of effective GLP-1 agonists like Novo's semaglutide and liraglutide, and Lilly's tirzepatide.


Why it matters: The development of an oral GLP-1 receptor agonist like CT996 could revolutionize the treatment of type 2 diabetes and obesity by providing a more convenient alternative to injections. This innovation highlights the ongoing competition in the GLP-1 market, which is likely to result in more options and potentially better pricing for patients.


Fractyl Health Receives FDA Breakthrough Device Designation for Revita

Fractyl Health has received FDA Breakthrough Device Designation for its Revita system, designed for weight maintenance in patients who discontinue GLP-1 drugs. Revita aims to address the high rates of weight regain experienced by patients after stopping GLP-1 medications. The device uses hydrothermal ablation to remodel the duodenal lining, targeting a root cause of metabolic disease.


Why it matters: The FDA Breakthrough Device Designation for Revita highlights the importance of finding sustainable weight maintenance solutions for patients discontinuing GLP-1 drugs. With high rates of weight regain post-GLP-1 treatment, Revita could provide a crucial off-ramp, helping patients maintain their weight loss without continuous medication.


Novo Nordisk's GLP-1 Liraglutide May Slow Alzheimer's Progression

Novo Nordisk's GLP-1 drug liraglutide, known for its use in diabetes and obesity treatment, may also have the potential to slow the progression of Alzheimer's disease. Preliminary research suggests that liraglutide could offer neuroprotective benefits, potentially opening new avenues for Alzheimer's therapy. This finding is part of a growing body of research exploring the broader applications of GLP-1 receptor agonists.


Why it matters: Discovering new therapeutic uses for existing medications like liraglutide can significantly impact the treatment landscape for complex diseases such as Alzheimer's. This research underscores the importance of continued investigation into the multifaceted benefits of GLP-1 receptor agonists, potentially improving the lives of millions affected by Alzheimer's disease.


How GLP-1 Drugs Treat Obstructive Sleep Apnea

Dr. Anne Marie Morse explains that GLP-1 receptor agonists such as semaglutide and tirzepatide, already FDA-approved for obesity and diabetes, may also reduce symptoms in patients with obstructive sleep apnea (OSA). These drugs not only aid in weight loss but also potentially improve upper airway tone, enhancing sleep quality. Dr. Morse emphasizes the broader applications of GLP-1 drugs, highlighting their role in treating multiple conditions beyond their primary indications.


Why it matters: The potential use of GLP-1 drugs in treating obstructive sleep apnea offers a new therapeutic avenue for patients. By addressing both weight management and sleep disorders, GLP-1 receptor agonists could provide comprehensive health benefits, improving the quality of life for individuals with OSA. This underscores the need for further research and clinical trials to validate these findings and expand treatment options.


Expert Tweet of the Week


From @EricTopol


"Western diets are pro-inflammatory and a recipe for chronic disease risk"

@NatureMedicine

Read the related article here


---


Our ModernWeight "Weekly Weight Management Insights" newsletter is designed to keep you informed and engaged with the latest in weight management and GLP-1 medications. Visit the Social Hub to join the conversation and connect with our community.


Want to receive this newsletter in your inbox weekly? Create a profile!




4 views0 comments

ความคิดเห็น


bottom of page